Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 528-538

  Miller, Vincent A ^a,b   Hirsh, Vera ^c   Cadranel, Jacques ^d   Chen, Yuh Min ^e   Park, Keunchil ^f   Kim, Sang We ^g   Zhou, Caicun ^h   Su, Wu Chou ⁱ   Wang, Mengzhao ^j   Sun, Yan ^k   Heo, Dae Seog ^l   Crino, Lucio ^m   Tan, Eng Huat ⁿ   Chao, Tsu Yi ^o   Shahidi, Mehdi ^p   Cong, Xiuyu Julie ^q   Lorence, Robert M ^q   Yang, James Chih Hsin ^r  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d HÔPITAL TENON   (France)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f Samsung Medical Center   (South Korea)

^g Asan Medical Center   (South Korea)

^h TONGJI UNIVERSITY   (China)

ⁱ NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^j PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^k CANCER HOSPITAL   (China)

^l Seoul National University Hospital   (South Korea)

^m SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

ⁿ DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^o TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^p BOEHRINGER INGELHEIM LTD   (United Kingdom)

^q BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^r NATIONAL TAIWAN UNIVERSITY   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; PLACEBO;

ACNE; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARM PAIN; ARTICLE; BACKACHE; CANCER STAGING; CANCER SURVIVAL; CONSTIPATION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; DYSGEUSIA; DYSPNEA; EPISTAXIS; EYE DISEASE; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HEADACHE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOKALEMIA; INSOMNIA; KIDNEY FAILURE; LEG PAIN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; RHINORRHEA; SIDE EFFECT; STOMATITIS; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUINAZOLINES;

EID: 84862785051     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70087-6     Document Type: Article

References (31)

1. Pao W, Miller VA Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005, 23:2556-2568.
2. Kobayashi S, Ji H, Yuza Y, et al. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 2005, 65:7096-7101.
3. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011, 17:1616-1622.
4. Li D, Ambrogio L, Shimamura T, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008, 27:4702-4711.
5. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 2010, 28:3965-3972.
6. Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res 2010, 70:868-874.
7. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993, 85:365-376.
8. Bergman B, Aaronson NK, Ahmedzai S, Kaasa S, Sullivan M The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer 1994, 30A:635-642.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
10. Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A EORTC QLQ-C30 Scoring Manual 2001, European Organisation for Research and Treatment of Cancer, Brussels. third edn.
11. Robins JM, Finkelstein DM Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000, 56:779-788.
12. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012, 30:718-721.
13. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol 2010, 28:357-360.
14. Sholl LM, Xiao Y, Joshi V, et al. EGFR mutation is a better predictor of response to tyrosine kinase inhibitors in non-small cell lung carcinoma than FISH, CISH, and immunohistochemistry. Am J Clin Pathol 2010, 133:922-934.
15. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
16. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
17. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009, 361:947-957.
18. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 2010, 21:1804-1809.
19. Hirsh V, Cadranel J, Cong J, et al. Symptom and health-related quality of life benefit from afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib: results of a randomized phase III study (LUX-Lung 1). Proc World Conf Lung Cancer 2011, abstract number O11.07.
20. Pao W, Chmielecki J Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 2010, 10:760-774.
21. Heigener DF, Reck M Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib. Adv Ther 2011, 28:126-133.
22. Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007, 13:5150-5155.
23. Pietanza MC, Lynch TJ, Lara PN, et al. XL647-a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib. J Thorac Oncol 2012, 7:219-226.
24. Johnson ML, Riely GJ, Rizvi NA, et al. Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib. J Thorac Oncol 2011, 6:1128-1131.
25. Sequist LV, Besse B, Lynch TJ, et al. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol 2010, 28:3076-3083.
26. Janjigian YY, Azzoli CG, Krug LM, et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res 2011, 17:2521-2527.
27. Atagi S, Katakami N, Hinda T, et al. LUX-Lung 4: A phase II trial of afatinib (BIBW 2992) in advanced NSCLC patients previously treated with erlotinib or gefitinib. Proc World Conf Lung Cancer 2011, abstract number O19.06.
28. Lee J, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28:7525.
29. Pazdur R Endpoints for assessing drug activity in clinical trials. Oncologist 2008, 13(suppl 2):19-21.
30. Chaft JE, Oxnard GR, Sima CS, Kris MG, Miller VA, Riely GJ Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin Cancer Res 2011, 17:6298-6303.
31. Yang JC-H, Shih JY, Su W-C, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012, published online March 26. 10.1016/S1470-2045(12)70086-4.